OPtimized Stenting Using Intravascular Ultrasound(IVUS) in Long lEsion: Rationale for Simplified criteriA

Diabetes Clinical Trial

— OPERA  

Official title:

OPtimized Stenting Using IVUS in Long lEsion: Rationale for Simplified criteriA

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01861860
• Other study ID #: P12-37811002 / 2012-A00696-37
• Status: Completed
• Phase: N/A
• Start date: October 2012
• Est. completion date: July 2018

Study information

• Verified date: July 2018
• Source: Centre Chirurgical Marie Lannelongue
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rationale IVUS has shown to be efficient for bare metal stent deployment, but has not been specifically studied for Drug Eluting Stents. The angiographically versus IVUS optimization (AVIO) study was performed with (medical device's type )Promus stent, results are promising, but the study was not designed for clinical endpoint.

There is no consensus on IVUS criteria for stent deployment. The MUSIC criteria were widely used in the early 2000, but have limitations for complex long lesions. The AVIO criteria were recently proposed for complex lesions, but these criteria also have some issues and the complexity make their routine use challenging.

We performed a pilot study for long complex lesion analysis using IVUS, in order to define easy to use criteria, applicable for complex lesions in drug eluting stents (DES) era. The new criteria (OPERA) are an adaptation of the MUSIC criteria.

OTELLO study is an ongoing trial sponsored by Boston Scientific Inc, to determine Major Adverse Cardiac Event with the new TAXUS Element stent. 500 patients will be enrolled in the study.

Main question Is IVUS using simplified new criteria beneficial for long (>28mm) TAXUS element stent deployment?

Study design This study will consist to prospectively include consecutive patients with>28mm taxus element stent using IVUS. OPERA Criteria for stent deployment will be the objectives to reach. OPERA is an adaptation of the MUSIC criteria for long complex lesion. The patients from the OTELLO study, with the same inclusion criteria, will composed the control group . Population will be matched using the propensity score.

20 to 30 French centers involved in OTELLO study will be contacted for participating in OPERA.

Hypothesis:

Long lesion percutaneous coronary intervention(PCI) have specific characteristics like Diffuse old atheroma Calcifications Discrepancies between prox and distal diameter Infiltration longer than the target lesion Bifurcations Inhomogeneous strength due to the balloon (Laplace law) Primary hypothesis Long Taxus element deployed using IVUS and OPERA criteria have better outcomes than without IVUS

Primary Objectives 38% MACE (SAT, target lesion revascularization (TLR), myocardial infarction (MI), Death) reduction using IVUS and OPERA criteria for Taxus element ≥ 28 mm implantation

Secondary endpoint

1. MACE determination for Taxus element ≥ 28 mm implantation with IVUS and OPERA criteria

2. Safety: procedural Stroke, Urgent cardiac surgery, procedural MI

3. Comparison of IVUS criteria: OPERA, MUSIC, AVIO

Secondary objectives Safety of OPERA criteria Feasibility of using OPERA criteria in non expert IVUS center MACE determination with a 4% margin error for Taxus element ≥ 28 mm implantation with IVUS and OPERA criteria

Methods Inclusion of consecutive patients using IVUS Taxus element ≥ 28 mm in a multicentric study propensity score matched analysis matched for comparison to OTELLO study. (Same inclusion criteria as OTELLO)

Statistical analysis Primary Endpoint: MACE expected in the OTELLO study=18% MACE expected in the OPERA study=11% Number of patient in the OTELLO study=500 Alpha=0.05,1- Beta=0.73 Number of patients analysable in the OPERA study needed =250 patients i.e 300 pts inclusions.

Secondary Endpoint 4% margin error with a MACE of 11% need also 250 pts

Type of study Biomedical research French study Centralized IVUS analysis 1, 6 and 12 months telephone contact

Safety and efficacy measures Efficacy: MACE (Cardiac Death, target vessel revascularization (TVR), Myocardial Infarction) at 12 months Safety: procedure related event: Urgent surgery, According to Good Clinical Practices serious adverse event (SAE) declared within 24 Hours

Recruitment information / eligibility

• Status: Completed
• Enrollment: 300
• Est. completion date: July 2018
• Est. primary completion date: April 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years

• Patients who have had a coronary angioplasty with implantation of a TAXUS™ Element™ stent of 28, 32 and 38 mm in length and up to 3 stents per patient in the case of acute occlusive dissection deployed using IVUS

• Patients with indication of Taxus™ Element™ stent included in the List of Reimbursable Products and Supplies (LPPR):

• diabetes,

• small vessel (less than 3 mm in diameter),

• long lesion(s) (more than 15 mm long),

• chronic total occlusion > 1 month,

• intra-stent restenosis with the exclusion drug eluting stent(s), restenosis of

• people with a lesion that is accessible to IVUS after stenting

• people who have provided consent for collection of medical data for this trial.

Exclusion Criteria:

-Those who refuse to consent to the collection and/or processing of data necessary to complete the trial and/or the centralized follow-up

Related Conditions & MeSH terms

• Chronic Total Occlusion of Coronary Artery
• Coronary Artery Disease
• Coronary Disease
• Coronary Heart Disease
• Diabetes
• Heart Diseases
• Myocardial Ischemia
• Restenosis
• Vascular Lesions

Intervention

Device:
• TAXUS™ Element long stent
Segments are selected using bifurcation branch take-off. The reference is selected or estimated on both sides of the bifurcation and is applied to the concerned segment. The objective is to attain > 80% of the reference cross-sectional areas (CSA) per segment. The balloon diameter is adapted to the endoluminal diameter of the reference.

Locations

Country	Name	City	State
France	Centre Chirurgical Marie Lannelongue	Le Plessis Robinson	Ile De France

Sponsors (9)

Lead Sponsor	Collaborator
Centre Chirurgical Marie Lannelongue	Centre Hospitalier de La Rochelle, Centre Hospitalier de PAU, Centre Hospitalier Universitaire de Nice, Hôpital Cochin, Hôpital de la Timone, Rangueil Hospital, University Hospital, Limoges, Versailles Hospital

Country where clinical trial is conducted

France, 

References & Publications (3)

Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Yasuda T, Moussa I, Dangas G, Mehran R, Lansky AJ, Reyes A, Kreps E, Collins M, Colombo A, Stone GW, Teirstein PS, Leon MB, Moses JW. Contribution of stent underexpansion to recurrence after sirol — View Citation

Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting — View Citation

Sonoda S, Morino Y, Ako J, Terashima M, Hassan AH, Bonneau HN, Leon MB, Moses JW, Yock PG, Honda Y, Kuntz RE, Fitzgerald PJ; SIRIUS Investigators. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The incidence of MACE composite criteria among patients who received a TAXUS long stent deployed using IVUS according to the OPERA criteria according to the LPPR during a 12 months period after inclusion in the trial.	The MACE composite criteria includes all cardiac deaths and infarctions in the regions of treated lesions as well as revascularization of treated lesions (via iterative angioplasty or aortocoronary bypass) of lesion(s) that receive TAXUS long stent according to the Commission Evaluation of Products and Service (CEPP) over a 12 months period after inclusion in the trial.; To demonstrate improvement of MACE during deployment of 28, 32 and 38 mm TAXUS™ Element™ stents using IVUS. The main objective of the trial is the collection of health data, especially the rate of serious cardiac events at 12 months in the indications recognized by the LPPR. These events are represented by a MACE composite criteria at 1 year, including all cardiac deaths and infarctions in the region of the stented artery and revascularization of the stented artery (TVR) where the reference population is the OTELLO population.	12 months period after inclusion in the trial
Secondary	The incidence of the MACE composite criteria at 6 months, 12 months and 3 years.		6 months, 12 months and 3 years
Secondary	The incidence of individual components of the MACE composite criteria at 6 months, 12 months and 3 years.	Cardiac deaths and infarctions in the region of the stented artery, revascularization of the stented artery	6 months, 12 months and 3 years
Secondary	The occurrence of follow-on events over a period of 6 months, 12 months and 3 years.	Death from all causes, all myocardia infarctions, all revascularizations.	6 months, 12 months and 3 years
Secondary	Stent thrombosis at 12 months		12 months
Secondary	Medico-economics data at 12 months including	the number of secondary hospitalizations for cardiac problems; the number of hospitalizations for problem non cardiac but associated with the procedure; the number of new coronary angiographies; the number de new angioplasties; the number of Coronary Artery Bypass Grafting (CABG); the number and type of other additional examinations; the number and type of special consultations during the monitoring period	At 12 months including